Scroll

amisulpride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sulpiride derivatives and analogues	179	71675-85-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: barhemsys amisulpride aminosultopride deniban solian	A benzamide derivative that is used as an antipsychotic agent for the treatment of schizophrenia. It is also used as an antidepressive agent. Molecular weight: 369.48 Formula: C17H27N3O4S CLOGP: 1.97 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 101.73 ALOGS: -3.10 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

barhemsys
amisulpride
aminosultopride
deniban
solian

A benzamide derivative that is used as an antipsychotic agent for the treatment of schizophrenia. It is also used as an antidepressive agent.

Molecular weight: 369.48
Formula: C17H27N3O4S
CLOGP: 1.97
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 101.73
ALOGS: -3.10
ROTB: 7

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
7.50	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	50 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	48 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	46.40 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.52 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 26, 2020	FDA	ACACIA PHARMA LTD
Jan. 1, 1986	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Extrapyramidal disorder	314.09	26.25	102	8339	13182	63467399
Schizophrenia	221.39	26.25	73	8368	9879	63470702
Hyperprolactinaemia	160.97	26.25	46	8395	3854	63476727
Blood prolactin increased	156.71	26.25	44	8397	3459	63477122
Sopor	151.79	26.25	69	8372	22095	63458486
Drug abuse	146.39	26.25	101	8340	72417	63408164
Mental impairment	142.92	26.25	58	8383	14093	63466488
Akathisia	137.18	26.25	50	8391	9096	63471485
Refusal of examination	112.21	26.25	20	8421	183	63480398
Neuroleptic malignant syndrome	100.15	26.25	43	8398	12013	63468568

Showing 1 to 10 of 95 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	441.75	25.71	112	10974	2435	34943410
Akathisia	363.72	25.71	125	10961	7984	34937861
Disinhibition	341.42	25.71	96	10990	3130	34942715
Therapeutic product effect variable	324.39	25.71	87	10999	2369	34943476
Obsessive-compulsive disorder	318.11	25.71	103	10983	5461	34940384
Euphoric mood	292.53	25.71	97	10989	5544	34940301
Increased appetite	266.38	25.71	97	10989	7332	34938513
Schizophrenia	230.59	25.71	91	10995	8575	34937270
Suicide attempt	205.17	25.71	137	10949	38979	34906866
Neuroleptic malignant syndrome	192.78	25.71	100	10986	17834	34928011

Showing 1 to 10 of 80 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Extrapyramidal disorder	435.29	22.27	166	15947	22513	79705762
Schizophrenia	347.31	22.27	127	15986	15313	79712962
Neuroleptic malignant syndrome	285.60	22.27	130	15983	27429	79700846
Akathisia	254.11	22.27	97	16016	13162	79715113
Electrocardiogram QT prolonged	223.77	22.27	168	15945	90218	79638057
Hyperprolactinaemia	215.34	22.27	66	16047	4610	79723665
Blood prolactin increased	207.84	22.27	62	16051	3949	79724326
Mental impairment	207.34	22.27	93	16020	18943	79709332
Antipsychotic drug level increased	195.62	22.27	65	16048	5892	79722383
Antipsychotic drug level below therapeutic	183.79	22.27	44	16069	1194	79727081

Showing 1 to 10 of 158 entries

Previous1 2 3 4 5…16Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05AL05	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:65191	atypical antipsychotic agent
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000175800	Dopamine-2 Receptor Antagonist
FDA MoA	N0000175799	Dopamine D2 Antagonists
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Postoperative nausea and vomiting	indication	1488000
Chronic schizophrenia	indication	83746006
Dysthymia	off-label use	78667006	DOID:12139

Showing 1 to 3 of 3 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.78	acidic
pKa2	9.09	Basic
pKa3	0.54	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9545426	March 10, 2031	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9545426	March 10, 2031	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9889118	March 10, 2031	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9889118	March 10, 2031	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9084765	Feb. 26, 2034	PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9084765	Feb. 26, 2034	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	9084765	Feb. 26, 2034	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	11357753	Feb. 9, 2038	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
5MG/2ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Feb. 26, 2020	RX	SOLUTION	INTRAVENOUS	9545426	March 10, 2031	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
5MG/2ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Feb. 26, 2020	RX	SOLUTION	INTRAVENOUS	9545426	March 10, 2031	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

Showing 1 to 10 of 16 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG/4ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Sept. 1, 2020	RX	SOLUTION	INTRAVENOUS	Feb. 26, 2025	NEW CHEMICAL ENTITY
5MG/2ML (2.5MG/ML)	BARHEMSYS	ACACIA	N209510	Feb. 26, 2020	RX	SOLUTION	INTRAVENOUS	Feb. 26, 2025	NEW CHEMICAL ENTITY

Showing 1 to 2 of 2 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.55	WOMBAT-PK	SCIENTIFIC LITERATURE
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.50	WOMBAT-PK	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.08	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.89	PDSP
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.38	PDSP
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	7.94	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.87	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	5.81	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.63	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	5.76	PDSP

Showing 1 to 10 of 12 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
005229	NDDF
17788	MMSL
2159	PUBCHEM_CID
2284233	RXNORM
321636003	SNOMEDCT_US
331491	MMSL
391761004	SNOMEDCT_US
4039609	VANDF
4960	INN_ID
8110R61I4U	UNII

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Barhemsys	HUMAN PRESCRIPTION DRUG LABEL	1	71390-125	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	NDA	30 sections
Barhemsys	HUMAN PRESCRIPTION DRUG LABEL	1	71390-125	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	NDA	30 sections

Showing 1 to 2 of 2 entries

Previous1Next